Hui-Qiang Huang

Sun Yat-sen University — China

Medicine · Health Sciences

27h-index2.1kcitations65works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(50), Viral-associated cancers and disorders(34), Immune Cell Function and Interaction(17), CNS Lymphoma Diagnosis and Treatment(10), Chronic Lymphocytic Leukemia Research(8)

Publications65 total

Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study
Blood·2025Open Access
Long-term outcomes of a novel initial regimen: Rituximab plus pegylated interferon α-2b in untreated advanced indolent B-cell lymphoma – 5-year follow-up of the ripple study
Blood·2025
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial
Blood·2025Open Access
Combination of mitoxantrone hydrochloride liposome with tislelizumab in patients with relapsed or refractory NK/T cell lymphoma: A phase Ib/II study.
Journal of Clinical Oncology·2025
Sintilimab (anti-PD-1 antibody) combined with chidamide (an oral subtype-selective HDACi) followed by P-GemOx regimen in patients with treatment-naïve extranodal natural killer/T cell lymphoma (TN-ENKTL): A multicenter, open-label, single-arm, phase II study (SCENT-2 trial).
Journal of Clinical Oncology·2025
Safety, Efficacy, and Pharmacokinetics of Unecritinib (TQ-B3101) in Pediatric Patients with Relapsed/Refractory Anaplastic Lymphoma Kinase Positive Anaplastic Large Cell Lymphoma: A Phase I Study
Blood·2024
Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study
Blood·2024
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study
Leukemia·2020· 30 citedOpen Access
First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG
Blood Advances·2020· 56 citedOpen Access
A gene-expression-based signature predicts survival in adults with T-cell lymphoblastic lymphoma: a multicenter study
Leukemia·2020· 36 cited
Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma
Leukemia·2019· 71 cited
Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein–Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol
Leukemia & lymphoma/Leukemia and lymphoma·2019· 18 cited
Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma
Leukemia·2018· 122 citedOpen Access
Persistent peripheral blood EBV-DNA positive with high expression of PD-L1 and upregulation of CD4 + CD25 + T cell ratio in early stage NK/T cell lymphoma patients may predict worse outcome
Annals of Hematology·2018· 10 cited
Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study
The Lancet Oncology·2018· 216 cited
Overexpression of MYC and BCL2 Predicts Poor Prognosis in Patients with Extranodal NK/T-cell Lymphoma, Nasal Type
Journal of Cancer·2017· 35 citedOpen Access
Radiotherapy improves survival in early stage extranodal natural killer/T cell lymphoma patients receiving asparaginase-based chemotherapy
Oncotarget·2016· 15 citedOpen Access
Radiation dose reduction for patients with extranodal NK/T-cell lymphoma with complete response after initial induction chemotherapy
OncoTargets and Therapy·2016· 11 citedOpen Access
High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients
Oncotarget·2016· 53 citedOpen Access
Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma
Oncotarget·2016· 59 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Wen-Qi Jiang(30), Zhong-Jun Xia(27), Tong-Yu Lin(21), Zhiming Li(17), Yi Xia(16), Jia-Jia Huang(11), Qing-Qing Cai(11), Yue Lu(10), Liang Wang(9), Yu‐Jing Zhang(9), Ya-Jun Li(7), Hui-Lan Rao(7), Xiao-Xiao Wang(7), Qi-Chun Cai(6), Yan Gao(6), Hua Wang(6), Ying-Jie Zhu(5), Xiao-Fei Sun(5), Zhong-Zhen Guan(5), Ze-Xiao Lin(4)